Subscribe

Subscribe to CONQUER: the patient voice™ magazine

Receive timely cancer news & updates, patient stories, and more.

First Name *
Last Name *
Need multiple copies? Click here
 
 
Subscribe

Subscribe to CONQUER: the patient voice™ magazine

Receive timely cancer news & updates, patient stories, and more.

First Name *
Last Name *
Need multiple copies? Click here
 
FDA NewsLymphomaNewsworthy

Calquence Newest Treatment Approved for Mantle-Cell Lymphoma

In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
December 2017 Vol 3 No 6

On October 31, 2017, the FDA accelerated the approval of Calquence (acalabrutinib; from AstraZeneca) for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy. Mantle-cell lymphoma is a rare and fast-growing type of non-Hodgkin lymphoma.

“Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “For patients who have not responded to treatment or have relapsed, Calquence provides a new treatment option that has shown high rates of response for some patients in initial studies.”

This approval was based on a clinical trial of patients with mantle-cell lymphoma that showed that 81% of patients who received Calquence had a complete or partial response to this drug. Serious side effects with Calquence include bleeding, infections, and irregular heartbeat. Women who breastfeed should not take this drug. In addition, new cases of cancer occurred in some patients who used Calquence.

Recommended For You
Last modified: January 16, 2018